IsoRay (NYSEAMERICAN:ISR) Sees Large Volume Increase on Strong Earnings

IsoRay, Inc. (NYSEAMERICAN:ISR) shares saw unusually-strong trading volume on Wednesday after the company announced better than expected quarterly earnings. Approximately 777,300 shares traded hands during trading, an increase of 407% from the previous session’s volume of 153,379 shares.The stock last traded at $0.37 and had previously closed at $0.34.

The healthcare company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. The business had revenue of $2.32 million during the quarter, compared to analysts’ expectations of $2.23 million.

Separately, Zacks Investment Research upgraded shares of IsoRay from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a report on Saturday, September 28th.

An institutional investor recently raised its position in IsoRay stock. Vanguard Group Inc. boosted its holdings in IsoRay, Inc. (NYSEAMERICAN:ISR) by 11.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,594,907 shares of the healthcare company’s stock after purchasing an additional 169,100 shares during the quarter. Vanguard Group Inc. owned approximately 2.37% of IsoRay worth $654,000 at the end of the most recent quarter.

The business’s fifty day simple moving average is $0.34 and its 200 day simple moving average is $0.39.

IsoRay Company Profile (NYSEAMERICAN:ISR)

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

See Also: What is a balanced fund?

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.